BR55

DRUG5 trials

Sponsors

Bracco Diagnostics, Inc

Conditions

Ovarian CancerPancreatic Ductal AdenocarcinomaProstate Cancer

Early Phase 1

BR55 in Prostate Cancer: an Exploratory Clinical Trial

CompletedNCT01253213

Bracco Diagnostics, IncProstate Cancer

Start: 2010-07-31End: 2012-12-31Updated: 2023-08-01

Phase 1

A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer

CompletedNCT02142608

Bracco Diagnostics, IncProstate Cancer

Start: 2014-08-31End: 2016-01-31Updated: 2021-03-29

Phase 2

Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

TerminatedNCT03486327

Bracco Diagnostics, IncPancreatic Ductal Adenocarcinoma

Start: 2018-07-19End: 2021-07-31Updated: 2024-08-23

BR55 in Characterization of Ovarian Lesions

TerminatedNCT03493464

Bracco Diagnostics, IncOvarian Cancer

Start: 2018-12-13End: 2021-07-31Updated: 2024-09-19

Optimal Timing of BR55 CEUS of the Ovaries

TerminatedNCT04248153

Bracco Diagnostics, IncOvarian Cancer

Start: 2019-10-14End: 2021-07-31Updated: 2024-08-23